Pfizer pledges $100M for antimicrobial resistance
Pfizer has pledged $100 million to the Antimicrobial Resistance Action Fund to address the need for new antibiotics due to the rapid rise of antibiotic-resistant infections. Read More
$1.6B awarded to Novavax for COVID-19 vaccine
Novavax was awarded $1.6 billion by the U.S. government through Operation Warp Speed to deliver 100 million doses of a COVID-19 vaccine as early as late 2020. Read More
Illumina introduces sequencing software for rare genetic diseases
Illumina has launched software that facilitates whole genome sequencing for rapid identification of rare genetic diseases. Read More
Group calls for consistent use of genetic cancer terms
A consortium of cancer patient advocacy groups and other stakeholders has recommended uniform use of common terms for biomarker and germline genetic testing to better educate the public and improve access. Read More
Xencor, Atreca to work on T cell-based cancer therapies
Biopharmaceutical company Xencor and biotechnology company Atreca have entered into a license agreement to research, develop, and commercialize T cell-engaging bispecific antibodies as potential cancer therapies. Read More
Reverie Labs, Roche to advance kinase drug discovery
Reverie Labs is partnering with Roche and Genentech to advance next-generation kinase inhibitors with the use of artificial intelligence. Read More
Constant Therapeutics to begin phase II trial for COVID-19 therapy
Constant Therapeutics' peptide drug TXA127 will advance to phase II clinical trials for the treatment of hospitalized COVID-19 patients. Read More
CEPI expands Clover partnership on COVID-19 vaccine
The Coalition for Epidemic Prepardeness Innovations (CEPI) has expanded its partnership with Clover Biopharmaceuticals for the development and manufacture of Clover's COVID-19 S-Trimer vaccine candidate. Read More
BD to provide injection devices for mass doses of COVID-19 vaccines
Becton Dickinson (BD) formed a strategic partnership with the Biomedical Advanced Research and Development Authority to develop new manufacturing lines for injection devices that will provide the U.S. government with hundreds of millions of syringes and needles to support pandemic vaccination efforts. Read More
Cancer Research UK, Abcam partner on cancer antibodies
Abcam will create protein-based reagents for targets identified by Cancer UK-funded researchers. Antibodies that result from the partnership will be used to further understand cancer biology, create new diagnostic tools, and potentially develop novel therapies. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
